KR102444803B1 - 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제 - Google Patents

신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제 Download PDF

Info

Publication number
KR102444803B1
KR102444803B1 KR1020217033764A KR20217033764A KR102444803B1 KR 102444803 B1 KR102444803 B1 KR 102444803B1 KR 1020217033764 A KR1020217033764 A KR 1020217033764A KR 20217033764 A KR20217033764 A KR 20217033764A KR 102444803 B1 KR102444803 B1 KR 102444803B1
Authority
KR
South Korea
Prior art keywords
formula
compound
propan
dex
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217033764A
Other languages
English (en)
Korean (ko)
Other versions
KR20210130827A (ko
Inventor
스리니바사라오 베파체두
한스 제이. 뫼비우스
안톤 베스팔로브
Original Assignee
익스시바 게엠베하
스리니바사라오 베파체두
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/en
Application filed by 익스시바 게엠베하, 스리니바사라오 베파체두 filed Critical 익스시바 게엠베하
Publication of KR20210130827A publication Critical patent/KR20210130827A/ko
Application granted granted Critical
Publication of KR102444803B1 publication Critical patent/KR102444803B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020217033764A 2017-05-04 2018-05-03 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제 Active KR102444803B1 (ko)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
US62/501,696 2017-05-04
USPCT/US2017/048748 2017-08-25
PCT/US2017/048748 WO2018039642A1 (en) 2016-08-26 2017-08-25 Compositions and methods thereof
TW106129169 2017-08-28
TW106129169A TW201815387A (zh) 2016-08-26 2017-08-28 組成物及其方法
US201862634162P 2018-02-22 2018-02-22
US62/634,162 2018-02-22
US201862635554P 2018-02-27 2018-02-27
US201862636099P 2018-02-27 2018-02-27
US62/636,099 2018-02-27
US62/635,554 2018-02-27
US201862636171P 2018-02-28 2018-02-28
US62/636,171 2018-02-28
KR1020197035796A KR20200062078A (ko) 2017-05-04 2018-05-03 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제
PCT/US2018/030978 WO2018204713A1 (en) 2017-05-04 2018-05-03 Targeted drug rescue with novel compositions, combinations, and methods thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197035796A Division KR20200062078A (ko) 2017-05-04 2018-05-03 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제

Publications (2)

Publication Number Publication Date
KR20210130827A KR20210130827A (ko) 2021-11-01
KR102444803B1 true KR102444803B1 (ko) 2022-09-19

Family

ID=65431106

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197035796A Ceased KR20200062078A (ko) 2017-05-04 2018-05-03 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제
KR1020217033764A Active KR102444803B1 (ko) 2017-05-04 2018-05-03 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197035796A Ceased KR20200062078A (ko) 2017-05-04 2018-05-03 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제

Country Status (13)

Country Link
EP (1) EP3618819A4 (enExample)
JP (2) JP7514078B2 (enExample)
KR (2) KR20200062078A (enExample)
CN (1) CN110831584B (enExample)
AU (2) AU2018261654A1 (enExample)
BR (1) BR112019022902A2 (enExample)
CA (2) CA3138116A1 (enExample)
IL (1) IL270326B2 (enExample)
MA (1) MA49464A (enExample)
RU (1) RU2760558C9 (enExample)
TW (1) TWI787260B (enExample)
WO (1) WO2018204713A1 (enExample)
ZA (1) ZA201908006B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204713A1 (en) * 2017-05-04 2018-11-08 Exciva Ug (Haftungsbeschränkt) Targeted drug rescue with novel compositions, combinations, and methods thereof
WO2020190971A1 (en) * 2019-03-18 2020-09-24 Avanir Pharmaceuticals, Inc. Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
JP7400818B2 (ja) * 2019-06-06 2023-12-19 Jsr株式会社 感放射線性樹脂組成物、レジストパターン形成方法及び化合物
CN115667217A (zh) 2020-05-19 2023-01-31 赛本爱尔兰有限公司 氘化的色胺衍生物和使用方法
CN116473073A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法
CN116473077B (zh) * 2023-05-08 2025-04-11 广东方中高新材料有限公司 一种n,n配位的镓配合物抗菌剂的合成和应用
CN119432479B (zh) * 2023-08-04 2025-10-03 中国石油天然气股份有限公司 柴油机润滑油组合物及其制备方法
CN120987847A (zh) * 2024-11-29 2025-11-21 江苏恩华药业股份有限公司 一种氢溴酸右美沙芬的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
AU2007212586A1 (en) 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
ATE546449T1 (de) * 2007-05-01 2012-03-15 Concert Pharmaceuticals Inc Morphinanverbindungen
CA2688784A1 (en) * 2007-05-21 2008-11-27 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP2964022B1 (en) * 2013-03-07 2019-11-06 Mindlab LLC Pain medicine combination and uses thereof
CA2907357A1 (en) * 2013-03-15 2014-09-18 Kinemed, Inc. Biomarkers
AU2015314710A1 (en) * 2014-09-14 2017-04-20 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
WO2018039642A1 (en) * 2016-08-26 2018-03-01 Exciva Ug (Haftungsbeschränkt) Compositions and methods thereof
WO2018204713A1 (en) * 2017-05-04 2018-11-08 Exciva Ug (Haftungsbeschränkt) Targeted drug rescue with novel compositions, combinations, and methods thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chem. Res. Toxicol. 22(2) (2009.) 1부.*
JAMA. 314(12):1242-1254(2015.9.22.) 1부.*
Pharmacology, Biochemistry and Behavior 94, 570-574 (2010) 1부.*

Also Published As

Publication number Publication date
ZA201908006B (en) 2021-04-28
WO2018204713A1 (en) 2018-11-08
KR20210130827A (ko) 2021-11-01
CN110831584A (zh) 2020-02-21
RU2019137004A (ru) 2021-06-04
TW201842902A (zh) 2018-12-16
IL270326B (en) 2022-10-01
CA3062452A1 (en) 2018-11-08
RU2760558C2 (ru) 2021-11-29
AU2021215274B2 (en) 2022-11-03
JP2023143940A (ja) 2023-10-06
RU2760558C9 (ru) 2022-02-22
JP2020518617A (ja) 2020-06-25
CN110831584B (zh) 2023-03-10
BR112019022902A2 (pt) 2020-05-19
IL270326B2 (en) 2023-02-01
JP7514078B2 (ja) 2024-07-10
RU2019137004A3 (enExample) 2021-06-04
TWI787260B (zh) 2022-12-21
CA3138116A1 (en) 2018-11-08
CA3062452C (en) 2023-10-24
IL270326A (enExample) 2018-05-03
EP3618819A1 (en) 2020-03-11
KR20200062078A (ko) 2020-06-03
AU2018261654A1 (en) 2019-11-14
MA49464A (fr) 2020-04-29
EP3618819A4 (en) 2021-01-20
AU2021215274A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
KR102444803B1 (ko) 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제
JP7096813B2 (ja) 組成物及びその方法
US20200261442A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
US20230382885A1 (en) Enantiomeric entactogen compositions and their use
CA3179785A1 (en) Advantageous benzofuran compositions for mental disorders or enhancement
EP2040755B1 (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
JP5226053B2 (ja) ベンジルイソキノリン誘導体またはビスベンジルイソキノリン誘導体を含有する向精神薬、鎮痛薬および／または抗炎症薬、ならびに健康食品
US20200069674A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
KR20230154219A (ko) 세로토닌성 작용제와 관련된 장애의 치료에 유용한 세로토닌성 작용제로서의 인돌 유도체
US20220296586A1 (en) Novel compositions, combinations, and methods thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4